Why Cutting a Keloid Out Often Makes It Worse: The Recurrence Problem, Explained

Ask anyone who has lived with a keloid for years and the most tempting option sounds obvious: just cut it off. Yet dermatologic surgeons consistently warn that excision by itself is one of the riskiest moves in keloid care. Published recurrence rates for surgery alone commonly fall in the range of 45 to 100 percent, and the regrown scar is frequently larger than the original. Understanding why requires looking at what a keloid actually is, because it is not simply excess scar tissue sitting on top of normal skin.

A keloid is a wound-healing program stuck in the on position. Normal healing moves through three overlapping phases: inflammation, proliferation, and remodeling. In most people, fibroblasts, the cells that lay down collagen, receive a stop signal once the wound is closed. In keloid-prone skin, that stop signal never fully arrives. Fibroblasts inside a keloid remain hyperactive, overproduce type I and type III collagen, and respond abnormally to growth factors, especially transforming growth factor beta, often shortened to TGF-beta. The result is a scar that grows beyond the boundaries of the original injury and keeps expanding, sometimes for years.

Surgery is, by definition, a new injury. When a surgeon excises a keloid, the incision reactivates the same wound-healing cascade that produced the keloid in the first place, in a patient whose biology has already demonstrated it cannot shut that cascade down. Worse, the fresh surgical wound is often longer than the base of the original lesion, which means the recurrent keloid has a larger footprint to colonize. This is why patients sometimes describe a small earlobe keloid returning after excision as a lesion twice its original size.

The margins problem makes things harder. Keloid tissue does not have a clean border. Histology studies show keloidal collagen and activated fibroblasts extending into skin that looks clinically normal. Even a technically flawless excision can leave behind cells that are already primed to overproduce collagen. This is different from removing, say, a cyst, where the target has a defined capsule.

So why do surgeons still operate on keloids? Because excision remains valuable when it is one component of a combination protocol rather than the entire plan. The goal of modern keloid surgery is debulking: remove the mass, then immediately suppress the healing response before it can overshoot. Several adjuncts have reasonable evidence behind them.

Intralesional corticosteroid injections, most often triamcinolone, are the workhorse. Steroids reduce fibroblast proliferation, suppress inflammatory signaling, and increase collagen breakdown. When injections begin at the time of surgery or shortly after, and continue on a schedule over weeks to months, recurrence rates in published series drop substantially compared with surgery alone, though results vary widely by site and study.

Superficial radiation therapy delivered within 24 to 72 hours of excision targets the rapidly dividing fibroblasts in the fresh wound. Multiple series report recurrence rates below 20 percent for excision plus radiation, and some report lower. The tradeoff is a small theoretical long-term risk that patients should discuss carefully, particularly for keloids near the breast or thyroid, and access to the equipment is uneven.

Pressure therapy has the strongest track record for earlobes. After earlobe keloid excision, wearing a pressure earring for many hours a day over several months appears to reduce recurrence, likely by limiting blood flow and mechanically restraining fibroblast activity. It is low tech, low risk, and adherence is the main obstacle.

Other adjuncts, including intralesional 5-fluorouracil, silicone sheeting, and imiquimod cream, occupy a middle tier: plausible mechanisms, mixed or smaller studies, and a role that often depends on the individual case and what else is being combined.

What patients should take from this. First, be skeptical of any plan that consists of excision and nothing else, especially for keloids on the chest, shoulders, or jawline, which sit in high-tension skin where recurrence pressure is greatest. Second, ask what the post-surgical suppression plan is before the surgery happens, not after. The window immediately following excision is when adjunct therapy matters most, because that is when the healing cascade is deciding whether to behave. Third, understand that even the best combination protocols do not guarantee a cure. Keloid biology is partly genetic, and success is better framed as long-term control than permanent elimination.

Finally, tension management matters more than it sounds. Techniques that close the wound with minimal pull on the skin edges, careful suture selection, and avoiding excision sites that cross high-tension lines all reduce the mechanical signaling that tells fibroblasts to keep building. Mechanotransduction, the process by which physical force is converted into cellular growth signals, is a genuine driver of keloid formation, not a footnote.

The short version: surgery is a tool, not a treatment. In keloid-prone skin, a scalpel without a suppression plan usually restarts the very process it was meant to end.

Related reading: Why Cutting a Keloid Out Often Makes It Bigger, and What Actually Lowers the Odds.